Hinge Health Inc (HNGE)

NYSE · Healthcare · Health Information Services · USA

Hinge Health Inc is a mid cap company (market value between $2 billion and $10 billion) in the Health Information Services industry.

Hinge Health delivers musculoskeletal care through AI-powered motion tracking, wearable devices, and a care team of licensed physical therapists, physicians, and health coaches. The company serves self-insured employers, health plans, and government programs, offering personalized remote treatment for acute injuries, chronic pain, and post-surgical rehabilitation.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Hinge Health Inc stock.

Our verdict on HNGE

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover three fiscal years and projecting growth needs four in a row.

ETFs with the most weight in HNGE

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Health Information Services

All 41 Health Information Services stocks

Compare side by side

Cheaper than HNGE in Health Information Services

15 more in this industry show a wider margin of safety.

Is HNGE undervalued or overvalued?

We do not publish a verdict on HNGE yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of HNGE?

We do not publish one (as of the 2026-10-20 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.